WO1995007729A1 - Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire - Google Patents
Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire Download PDFInfo
- Publication number
- WO1995007729A1 WO1995007729A1 PCT/EP1994/002842 EP9402842W WO9507729A1 WO 1995007729 A1 WO1995007729 A1 WO 1995007729A1 EP 9402842 W EP9402842 W EP 9402842W WO 9507729 A1 WO9507729 A1 WO 9507729A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- frequency
- oscillators
- mhz
- cellular system
- cell
- Prior art date
Links
- 230000001413 cellular effect Effects 0.000 title claims abstract description 16
- 230000037125 natural defense Effects 0.000 title claims abstract description 5
- 230000004936 stimulating effect Effects 0.000 title claims description 4
- 230000002503 metabolic effect Effects 0.000 claims abstract description 4
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 230000005672 electromagnetic field Effects 0.000 claims abstract description 3
- 239000002131 composite material Substances 0.000 claims description 4
- 239000003990 capacitor Substances 0.000 claims description 3
- 101000599778 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 claims description 2
- 101000988591 Homo sapiens Minor histocompatibility antigen H13 Proteins 0.000 claims description 2
- 101000960626 Homo sapiens Mitochondrial inner membrane protease subunit 2 Proteins 0.000 claims description 2
- 101000828788 Homo sapiens Signal peptide peptidase-like 3 Proteins 0.000 claims description 2
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 claims description 2
- 102100023501 Signal peptide peptidase-like 3 Human genes 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000005556 hormone Substances 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/002—Magnetotherapy in combination with another treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
Definitions
- the object of this invention is a device for stimulating the natural defenses of a person or of any cellular system, characterized by means for generating alternately electrical, magnetic and electromagnetic fields, at overlapping or sequentially ordered levels, with programmed modulations for creating therapeutic energy according to a certain code which resonates with the set of subatomic, atomic, molecular and cellular natural oscillators of an individual or of any cellular system, thus re- establishing metabolic equilibrium.
- the device creates the optimum electromagnetic environment for improving the development and functioning of any cell, whether a human, animal or plant cell.
- the device provides vital energy which, for many and sundry reasons, can become depleted. When this occurs, energy is transferred to those cells which need it, using very weak electromagnetic pulses which are virtually harmless to everyone.
- this device re-establishes cellular metabolism and thus also the metabolism of the entire ailing organism, creating—especially for the ailing elderly—a general sense of well-being, and improving general physiological activity by 90-100%.
- the device is also especially suitable for curing nerve, osteoarticular, arthritic, respiratory, blood, diabetic, and other disorders.
- Figure 1 shows the schematic of the device
- FIG. 2 is a block diagram. Descriptions follow which explain the device with regard to its conception.
- the basic conceptual principle is that of "recharging" the cellular unit.
- the transport, conversion and amplification of the signal received will allow the tissue cell or cells to respond in an appropriate manner, according to need.
- the initial composition that is, the receiving molecule present on the surface of the cell, transmits the information over the plasma membrane and inside this cell, by means of a family of proteins which function as transducers, called G proteins.
- G proteins activate an amplifier enzyme which is only located in the cell membrane; this transforms the precursor molecules into secondary messengers which spread out through the cell.
- the secondary messengers trigger some cellular proteins to modify their structure, with the result that the functioning of these proteins is activated or deactivated.
- the secondary messengers therefore, turn on or turn off the switches which control the activity of proteins, creating different conditions inside the cell. These conditions will determine the type of response the cell will give to signals received from the outside.
- the secondary messenger bonds to a component of an enzymatic protein, triggering the activity of the component which carries out enzyme functions.
- the mechanisms of signal transport and amplification are not necessary, while turning on or turning off the switch is done by the bond of the external signal.
- the action of receivers which have bonded the messenger can consist in selective opening of small pores or channels specific to given ions (for example, calcium) present in the cellular membrane.
- fat-soluble molecules steroid hormones
- the receivers for these hormones are located in the cytoplasm.
- proteins whose form is modified by the bond with the signal molecule.
- the modified protein enters the nucleus and becomes able to bond to DNA, the large molecule which preserves genetic information, at certain points, where it serves to control activation of the genes present at the point at which it is bound.
- This effect is known as primary response, in other cases secondary response, that is, the products of the primary response can have as a function—by bonding to DNA—that of activating other genes, amplifying and varying the response.
- Another method of controlling the response is to act on the receivers. After the water-soluble hormones bond with the appropriate receivers on the surface of the target cell, the cells often ingest them by endocytosis and destroy them. In this way, since there are either the same number or a lesser number of receivers, the capacity to respond to the hormones is also diminished.
- the receiver is "internalized” by endocytosis and preserved in vesicles, to be then reassembled on the cell membrane.
- Figure 1 shows the schematic of the device.
- the integrated circuit marked as IC2 acts as a pulse divider, and is a 12-stage binary device of the CMOS type.
- the integrated circuit marked as IC1 functions as a square wave oscillator, sending its composite signal to pin 10 of integrated circuit IC2, enabling the latter to generate from outputs 1-15-14-12-13 the proper stop/start pulses.
- the pulses will be spaced out by switch SI, which will make it possible, through passage of C18, to distinguish the signal coming from pin 5 of 1C1B.
- IC1D is amplified by the VHF power transistor, marked as TR4.
- TR4 VHF power transistor
- the output frequencies of transistors TRI and TR2 are matched by impedances IMP1 and IMP2 to a single intermediate frequency which will center on 12 MHz. From transistors TRI and TR2, which function as sequential power oscillators, it is possible to obtain, by continuous emissions, those which cover a frequency range from 20 to around 350 MHz. This type of "complex" wave will generate a considerable number of harmonics, since the emission will be modulated both in amplitude and in frequency.
- the passband which operates at a linear recurrence frequency, is around 100 MHz, and can generate much higher frequencies, emitting nonlinear square waves, with composite harmonics emitted which can reach 500 MHz.
- the two monostable adjustable oscillators at the NOR outputs of IC3 control the visual signal at the output through capacitors C13 and C17 by means of two LED diodes, marked on the diagram as DL1 and DL2 respectively.
- diodes DI and D2 as well as diodes D5 and D6 function as rectifiers of VHF signals, thus providing immediate display of the frequency intervals preselected, through switch SI.
- the circuit is powered with stabilized 24V direct current, with a maximum absorption of 30/35 mA.
- the device is installed in connection with a EUROCARD type card with dimensions of 100 x 160 mm.
- the 64-pin DIN 41612 on two wires is used as a terminal connector.
- the card marked with the designation 9301/M is installed in a standard 19" holder with a height equal to 3 units.
- Figure 2 shows a block diagram in which C is the converter, I.F. is the amplifier, M the modulator, A.F. the amplifier, 0 the oscillator.
- the signal is coded with n bits (0 or 1) , in fact is quantized in 2n levels.
- the time function which represents the signal, is sampled through the amplifier of F.I., while the amplitude of each sample is rounded off to the nearest of 2n levels admitted for transmission.
- the code used is binary code.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94926898A EP0669843A1 (fr) | 1993-09-13 | 1994-08-27 | Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire |
AU76558/94A AU7655894A (en) | 1993-09-13 | 1994-08-27 | Device for stimulating the natural defenses of a person or of any cellular system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH272893 | 1993-09-13 | ||
CH02728/93-0 | 1993-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995007729A1 true WO1995007729A1 (fr) | 1995-03-23 |
Family
ID=4240274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/002842 WO1995007729A1 (fr) | 1993-09-13 | 1994-08-27 | Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0669843A1 (fr) |
AU (1) | AU7655894A (fr) |
WO (1) | WO1995007729A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013549A1 (fr) * | 1995-10-10 | 1997-04-17 | Suleyman Seckiner Gorgun | Dispositif et procede de modulation des fonctions biologiques de structures biologiques |
WO2001070334A1 (fr) * | 2000-03-24 | 2001-09-27 | Active Medical Devices S.A. | Equipement conçu pour stimuler et optimiser la reorganisation biomoleculaire et cellulaire |
FR2820327A1 (fr) * | 2001-02-06 | 2002-08-09 | Mohamed Ayari | Procede pour l'obtention d'un ensemble de champs electromagnetiques a visees diagnostiques, preventives, therapeutiques et biotechnologiques |
AU751973B2 (en) * | 1997-10-17 | 2002-09-05 | Axel Muntermann | Device for magnetic field therapy |
WO2019178704A1 (fr) * | 2018-03-20 | 2019-09-26 | Novatech - Solutions Sa | Équipement conçu pour stimuler et optimiser la réorganisation biomoléculaire et cellulaire |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0136530A1 (fr) * | 1983-09-12 | 1985-04-10 | Dieter-Ernst Broers | Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques |
US4611599A (en) * | 1983-06-16 | 1986-09-16 | Richard Hugh Cameron Bentall | Electrical apparatus for influencing the metabolic characteristics of living systems |
CH667210A5 (de) * | 1981-11-24 | 1988-09-30 | Meguer V Kalfaian | Elektromagnetische bestrahlungsvorrichtung fuer therapeutische zwecke. |
EP0500983A1 (fr) * | 1991-02-28 | 1992-09-02 | Medi-Line Gmbh | Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques |
-
1994
- 1994-08-27 EP EP94926898A patent/EP0669843A1/fr not_active Withdrawn
- 1994-08-27 WO PCT/EP1994/002842 patent/WO1995007729A1/fr not_active Application Discontinuation
- 1994-08-27 AU AU76558/94A patent/AU7655894A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH667210A5 (de) * | 1981-11-24 | 1988-09-30 | Meguer V Kalfaian | Elektromagnetische bestrahlungsvorrichtung fuer therapeutische zwecke. |
US4611599A (en) * | 1983-06-16 | 1986-09-16 | Richard Hugh Cameron Bentall | Electrical apparatus for influencing the metabolic characteristics of living systems |
EP0136530A1 (fr) * | 1983-09-12 | 1985-04-10 | Dieter-Ernst Broers | Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques |
EP0500983A1 (fr) * | 1991-02-28 | 1992-09-02 | Medi-Line Gmbh | Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013549A1 (fr) * | 1995-10-10 | 1997-04-17 | Suleyman Seckiner Gorgun | Dispositif et procede de modulation des fonctions biologiques de structures biologiques |
AU751973B2 (en) * | 1997-10-17 | 2002-09-05 | Axel Muntermann | Device for magnetic field therapy |
WO2001070334A1 (fr) * | 2000-03-24 | 2001-09-27 | Active Medical Devices S.A. | Equipement conçu pour stimuler et optimiser la reorganisation biomoleculaire et cellulaire |
FR2820327A1 (fr) * | 2001-02-06 | 2002-08-09 | Mohamed Ayari | Procede pour l'obtention d'un ensemble de champs electromagnetiques a visees diagnostiques, preventives, therapeutiques et biotechnologiques |
WO2002062418A1 (fr) * | 2001-02-06 | 2002-08-15 | Mohamed Ayari | Ensemble de champs electromagnetiques a visees diagnostiques, preventives, therapeutiques |
WO2019178704A1 (fr) * | 2018-03-20 | 2019-09-26 | Novatech - Solutions Sa | Équipement conçu pour stimuler et optimiser la réorganisation biomoléculaire et cellulaire |
Also Published As
Publication number | Publication date |
---|---|
AU7655894A (en) | 1995-04-03 |
EP0669843A1 (fr) | 1995-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1575475B1 (fr) | Regulation de l'expression genique du collagene de type ii au moyen de signaux electriques et electromagnetiques specifiques et selectifs | |
EP1560553B1 (fr) | Régulation de l'expression du gène de l'aggrécane au moyen de signaux électriques et electromagnétiques spécifiques et sélectifs | |
US20010027278A1 (en) | Ultrasonic and growth factor bone-therapy: apparatus and method | |
EP1702648A3 (fr) | Système comprenant des appareils implantables pour surveiller et modifier des paramètres physiologiques d'un patient | |
ATE477018T1 (de) | Gerät zur ultraschall- und elektromagnetischen behandlung von gewebe | |
CA2308335A1 (fr) | Dispositif de magnetotherapie | |
TW201247180A (en) | Bio-medical unit system for medication control | |
EP1114829A3 (fr) | Les alloferons - modulateurs peptidiques immunitaires | |
DE69716596D1 (de) | Vorrichtung zur iontophoretischen verabreichung von medikamenten mit einem taststimulationsgenerator | |
CN101306228A (zh) | 电磁场与超声波复合治疗骨质疏松症的装置 | |
Hagi et al. | Augmenting effect of opioid peptides on murine macrophage activation | |
WO1995007729A1 (fr) | Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire | |
CN201094810Y (zh) | 电磁场与超声波复合治疗骨质疏松症的装置 | |
EP2359900A2 (fr) | Procédé de fixation de changements induits dans une structure d'un cristal initial sous l'action d'ondes acoustiques et électromagnétiques d'un milieu biologique et dispositif pour mettre en oeuvre le procédé, procédé de reproduction des changements d'une première structure cristalline d'un structure de cristal dupliqué (et variantes) et dispositif pour la mise en oeuvre de ce procédé (et variantes), et procédé pour effectuer une action sur un objet biologique (et variantes) | |
AU6567494A (en) | Amino sugars, glycoproteins, method of preparing them, medicines containing them and their use | |
WO2019178704A1 (fr) | Équipement conçu pour stimuler et optimiser la réorganisation biomoléculaire et cellulaire | |
AU4749900A (en) | Inactivated microorganisms comprising soluble and/or solubilizable substances having pharmacological activity and/or nutritional substances having pharmacological activity, the process for their preparation and their uses thereof | |
WO2001070334A1 (fr) | Equipement conçu pour stimuler et optimiser la reorganisation biomoleculaire et cellulaire | |
GB2292665A (en) | Pest control RF transmitter | |
Mulhall et al. | Prescriptive care? Guidelines and protocols | |
Azuma et al. | Acute hemolysis during cyclosporine therapy successfully treated with vitamin E | |
CN100435884C (zh) | 免疫治疗机 | |
AU2005225011A1 (en) | Electromagnetic treatment of mammals | |
Adams et al. | Peeper creepers. | |
Butz | Agriculture and Politics in the 1980's |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994926898 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994926898 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994926898 Country of ref document: EP |